Summary
Takara Bio Inc. (Takara), a subsidiary of Takara Holdings Inc. is a biotechnology company that develops, manufactures and distributes biotechnology research reagents and equipment. The company operates through three business divisions such as bio-industry, gene therapy, and agribio. Its bio-industry division offers sale of a gene amplification system known as PCR (polymerase chain reaction). Takara provides research reagents, scientific instruments, and contract research services. Its agribio business division produces and sells hatakeshimeji and honshimeji mushrooms. The company’s genetherapy division develops and commercializes medical technologies such as cell and gene therapies for cancer and AIDS. Takara is headquartered in Kusatsu, Japan.
Takara Bio Inc. (4974) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Takara Bio Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Takara Bio Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Takara Bio Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Takara Bio Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Takara Bio Inc., Medical Devices Deals, 2010 to YTD 2016 9
Takara Bio Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
Takara Bio Inc., Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Takara Bio Completes Acquisition Of HF10 Oncolytic Virus Business From M's Science 12
Partnerships 13
Clontech Labs Enters Into Technology Integration Agreement With Rubicon Genomics 13
Takara Bio Enters Into Co-Marketing Agreement With Exiqon For miRCURY LNA Products 15
Takara Bio Enters Into Research Agreement With TMUCIH 16
Takara Bio Forms Joint Venture With DSS Imagetech 17
NuGEN Enters Into Distribution Agreement With Takara 18
Takara Bio Enters Into Research Agreement With University of Pennsylvania 19
Licensing Agreements 20
MolMed and Takara Bio Terminate Licensing Agreement 20
Cellectis Enters into Licensing Agreement with Takara Bio for RetroNectin 21
Takara Bio Enters into Licensing Agreement with ViaCyte 22
Clontech Lab Enters into Licensing Agreement with Broad Institute for Crispr Gene Editing System 23
Takara Bio Expands Licensing Agreement With iPS Academia Japan 24
Takara Bio Enters Into Licensing Agreement With Cellular Dynamics International For RetroNectin 25
Eppendorf Enters Into Licensing Agreement With Takara Bio 26
ARIAD Pharma Enters Into Licensing Agreement With Clontech Labs 27
MDxHealth Enters Into Licensing Agreement With Takara Bio 29
Clontech Labs Enters Into Licensing Agreement With TET Systems Holding 30
Equity Offering 31
Takara Bio Prices Public Offering Of Common Stock For US$114.7 Million 31
Acquisition 32
Takara Bio Acquires Cellectis, Biotech Company 32
Takara Bio Inc. - Key Competitors 34
Key Employees 35
Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37
List of Tables
Takara Bio Inc., Pharmaceuticals & Healthcare, Key Facts, 2015 1
Takara Bio Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Takara Bio Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Takara Bio Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Takara Bio Inc., Deals By Therapy Area, 2010 to YTD 2016 8
Takara Bio Inc., Medical Devices Deals, 2010 to YTD 2016 9
Takara Bio Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
Takara Bio Completes Acquisition Of HF10 Oncolytic Virus Business From M's Science 12
Clontech Labs Enters Into Technology Integration Agreement With Rubicon Genomics 13
Takara Bio Enters Into Co-Marketing Agreement With Exiqon For miRCURY LNA Products 15
Takara Bio Enters Into Research Agreement With TMUCIH 16
Takara Bio Forms Joint Venture With DSS Imagetech 17
NuGEN Enters Into Distribution Agreement With Takara 18
Takara Bio Enters Into Research Agreement With University of Pennsylvania 19
MolMed and Takara Bio Terminate Licensing Agreement 20
Cellectis Enters into Licensing Agreement with Takara Bio for RetroNectin 21
Takara Bio Enters into Licensing Agreement with ViaCyte 22
Clontech Lab Enters into Licensing Agreement with Broad Institute for Crispr Gene Editing System 23
Takara Bio Expands Licensing Agreement With iPS Academia Japan 24
Takara Bio Enters Into Licensing Agreement With Cellular Dynamics International For RetroNectin 25
Eppendorf Enters Into Licensing Agreement With Takara Bio 26
ARIAD Pharma Enters Into Licensing Agreement With Clontech Labs 27
MDxHealth Enters Into Licensing Agreement With Takara Bio 29
Clontech Labs Enters Into Licensing Agreement With TET Systems Holding 30
Takara Bio Prices Public Offering Of Common Stock For US$114.7 Million 31
Takara Bio Acquires Cellectis, Biotech Company 32
Takara Bio Inc., Key Competitors 34
Takara Bio Inc., Key Employees 35
Takara Bio Inc., Subsidiaries 36
List of Figures
Takara Bio Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Takara Bio Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Takara Bio Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Takara Bio Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Takara Bio Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Takara Bio Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
Takara Bio Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Takara Bio Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Takara Bio Inc., Medical Devices Deals, 2010 to YTD 2016 9
